nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—kidney—membranous glomerulonephritis	0.0273	0.118	CbGeAlD
Thalidomide—NFKB1—cortex of kidney—membranous glomerulonephritis	0.0266	0.115	CbGeAlD
Thalidomide—CRBN—nephron tubule—membranous glomerulonephritis	0.026	0.112	CbGeAlD
Thalidomide—FGFR2—epithelium—membranous glomerulonephritis	0.0229	0.0986	CbGeAlD
Thalidomide—CRBN—cortex of kidney—membranous glomerulonephritis	0.0223	0.0961	CbGeAlD
Thalidomide—FGFR2—kidney—membranous glomerulonephritis	0.0205	0.0884	CbGeAlD
Thalidomide—CYP1A1—epithelium—membranous glomerulonephritis	0.00828	0.0357	CbGeAlD
Thalidomide—CYP3A5—nephron tubule—membranous glomerulonephritis	0.00826	0.0356	CbGeAlD
Thalidomide—CYP2E1—nephron tubule—membranous glomerulonephritis	0.0077	0.0332	CbGeAlD
Thalidomide—CYP1A1—kidney—membranous glomerulonephritis	0.00742	0.032	CbGeAlD
Thalidomide—PTGS1—epithelium—membranous glomerulonephritis	0.00727	0.0314	CbGeAlD
Thalidomide—CYP3A5—kidney—membranous glomerulonephritis	0.00726	0.0313	CbGeAlD
Thalidomide—CYP3A5—cortex of kidney—membranous glomerulonephritis	0.00707	0.0305	CbGeAlD
Thalidomide—PTGS2—epithelium—membranous glomerulonephritis	0.00695	0.03	CbGeAlD
Thalidomide—CYP2E1—kidney—membranous glomerulonephritis	0.00677	0.0292	CbGeAlD
Thalidomide—CYP2E1—cortex of kidney—membranous glomerulonephritis	0.00659	0.0284	CbGeAlD
Thalidomide—PTGS1—kidney—membranous glomerulonephritis	0.00652	0.0281	CbGeAlD
Thalidomide—PTGS2—kidney—membranous glomerulonephritis	0.00623	0.0269	CbGeAlD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—TBXAS1—membranous glomerulonephritis	0.00267	0.00347	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ABCA1—membranous glomerulonephritis	0.00265	0.00344	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—membranous glomerulonephritis	0.00264	0.00344	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—C3—membranous glomerulonephritis	0.00262	0.00341	CbGpPWpGaD
Thalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—membranous glomerulonephritis	0.00254	0.00331	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL1B—membranous glomerulonephritis	0.00254	0.00331	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—RHOA—membranous glomerulonephritis	0.00252	0.00328	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—MMP9—membranous glomerulonephritis	0.00247	0.00322	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—PLG—membranous glomerulonephritis	0.00246	0.0032	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD40—membranous glomerulonephritis	0.00246	0.0032	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—APOE—membranous glomerulonephritis	0.00244	0.00317	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—APOE—membranous glomerulonephritis	0.00244	0.00317	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—MMP9—membranous glomerulonephritis	0.00243	0.00316	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—membranous glomerulonephritis	0.00239	0.00312	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DRB1—membranous glomerulonephritis	0.00238	0.0031	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IL1B—membranous glomerulonephritis	0.00235	0.00306	CbGpPWpGaD
Thalidomide—NFKB1—p75 NTR receptor-mediated signalling—RHOA—membranous glomerulonephritis	0.00235	0.00306	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C7—membranous glomerulonephritis	0.00234	0.00304	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—CD79A—membranous glomerulonephritis	0.00231	0.00301	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—RHOA—membranous glomerulonephritis	0.0023	0.003	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—ALB—membranous glomerulonephritis	0.0023	0.00299	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—TBXAS1—membranous glomerulonephritis	0.00228	0.00297	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP9—membranous glomerulonephritis	0.00227	0.00296	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C7—membranous glomerulonephritis	0.00222	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP9—membranous glomerulonephritis	0.00222	0.00289	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—APOA1—membranous glomerulonephritis	0.00221	0.00287	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—IL1B—membranous glomerulonephritis	0.0022	0.00287	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—ALB—membranous glomerulonephritis	0.0022	0.00287	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—PLG—membranous glomerulonephritis	0.0022	0.00286	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—CD79A—membranous glomerulonephritis	0.00219	0.00286	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—RHOA—membranous glomerulonephritis	0.00219	0.00285	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—RHOA—membranous glomerulonephritis	0.00214	0.00279	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—IL1B—membranous glomerulonephritis	0.00212	0.00277	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ABCA1—membranous glomerulonephritis	0.0021	0.00273	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.00201	0.00262	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.00201	0.00262	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—PLG—membranous glomerulonephritis	0.00195	0.00254	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—APOE—membranous glomerulonephritis	0.0019	0.00247	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.0019	0.00247	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—RHOA—membranous glomerulonephritis	0.00189	0.00246	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—RHOA—membranous glomerulonephritis	0.00187	0.00243	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—IL1B—membranous glomerulonephritis	0.00187	0.00243	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CFH—membranous glomerulonephritis	0.00185	0.00241	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL1B—membranous glomerulonephritis	0.00184	0.00239	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL1B—membranous glomerulonephritis	0.00179	0.00233	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CFH—membranous glomerulonephritis	0.00176	0.00229	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—RHOA—membranous glomerulonephritis	0.00175	0.00228	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—ALB—membranous glomerulonephritis	0.00175	0.00228	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—APOA1—membranous glomerulonephritis	0.00172	0.00224	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL1B—membranous glomerulonephritis	0.00166	0.00216	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTPRU—membranous glomerulonephritis	0.00163	0.00212	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DQA1—membranous glomerulonephritis	0.0016	0.00208	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1B—membranous glomerulonephritis	0.00159	0.00207	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—ABCA1—membranous glomerulonephritis	0.00156	0.00203	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.00155	0.00202	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL1B—membranous glomerulonephritis	0.00155	0.00202	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—IL1B—membranous glomerulonephritis	0.00155	0.00202	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTPRU—membranous glomerulonephritis	0.00155	0.00201	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—membranous glomerulonephritis	0.00153	0.00199	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL1B—membranous glomerulonephritis	0.00142	0.00185	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.00142	0.00184	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—RHOA—membranous glomerulonephritis	0.00138	0.0018	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—APOA1—membranous glomerulonephritis	0.00137	0.00178	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ALB—membranous glomerulonephritis	0.00136	0.00177	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C7—membranous glomerulonephritis	0.00136	0.00177	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—RHOA—membranous glomerulonephritis	0.00134	0.00174	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—membranous glomerulonephritis	0.00131	0.00171	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL1B—membranous glomerulonephritis	0.0013	0.00169	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C7—membranous glomerulonephritis	0.00129	0.00168	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—membranous glomerulonephritis	0.00127	0.00165	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—TBXAS1—membranous glomerulonephritis	0.00121	0.00158	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL1B—membranous glomerulonephritis	0.00119	0.00155	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1B—membranous glomerulonephritis	0.00118	0.00154	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—MMP9—membranous glomerulonephritis	0.00115	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DRB1—membranous glomerulonephritis	0.00114	0.00148	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL1B—membranous glomerulonephritis	0.00113	0.00147	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1B—membranous glomerulonephritis	0.00111	0.00145	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL1B—membranous glomerulonephritis	0.00111	0.00144	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ALB—membranous glomerulonephritis	0.00108	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CFH—membranous glomerulonephritis	0.00108	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—RHOA—membranous glomerulonephritis	0.00107	0.00139	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MMP9—membranous glomerulonephritis	0.00106	0.00138	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—membranous glomerulonephritis	0.00105	0.00137	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.00103	0.00135	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CFH—membranous glomerulonephritis	0.00102	0.00133	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—APOA1—membranous glomerulonephritis	0.00101	0.00132	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—APOA1—membranous glomerulonephritis	0.000992	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD40—membranous glomerulonephritis	0.000992	0.00129	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—membranous glomerulonephritis	0.000988	0.00129	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD40—membranous glomerulonephritis	0.000941	0.00123	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD79A—membranous glomerulonephritis	0.000932	0.00121	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.000922	0.0012	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1B—membranous glomerulonephritis	0.000901	0.00117	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000888	0.00116	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD79A—membranous glomerulonephritis	0.000885	0.00115	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL1B—membranous glomerulonephritis	0.000881	0.00115	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—RHOA—membranous glomerulonephritis	0.000864	0.00113	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DQA1—membranous glomerulonephritis	0.000861	0.00112	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—IL1B—membranous glomerulonephritis	0.000849	0.00111	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—membranous glomerulonephritis	0.000837	0.00109	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—RHOA—membranous glomerulonephritis	0.000827	0.00108	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.000821	0.00107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—RHOA—membranous glomerulonephritis	0.00082	0.00107	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DQA1—membranous glomerulonephritis	0.000817	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Disease—LRP2—membranous glomerulonephritis	0.000784	0.00102	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—membranous glomerulonephritis	0.00076	0.00099	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1B—membranous glomerulonephritis	0.00074	0.000964	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.000732	0.000953	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.000729	0.000949	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—membranous glomerulonephritis	0.000721	0.000939	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000705	0.000918	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C3—membranous glomerulonephritis	0.0007	0.000911	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL1B—membranous glomerulonephritis	0.000696	0.000907	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—APOA1—membranous glomerulonephritis	0.000684	0.00089	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—C3—membranous glomerulonephritis	0.000672	0.000875	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C3—membranous glomerulonephritis	0.000664	0.000864	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—membranous glomerulonephritis	0.000657	0.000855	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.00065	0.000846	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—C3—membranous glomerulonephritis	0.000637	0.00083	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000626	0.000814	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—membranous glomerulonephritis	0.000612	0.000797	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40—membranous glomerulonephritis	0.000602	0.000783	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.000597	0.000777	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000594	0.000774	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—membranous glomerulonephritis	0.000581	0.000756	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LRP2—membranous glomerulonephritis	0.000579	0.000753	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40—membranous glomerulonephritis	0.000571	0.000743	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD79A—membranous glomerulonephritis	0.000566	0.000736	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—RHOA—membranous glomerulonephritis	0.000558	0.000727	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LRP2—membranous glomerulonephritis	0.000549	0.000715	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.000544	0.000708	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD79A—membranous glomerulonephritis	0.000537	0.000699	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.000532	0.000692	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQA1—membranous glomerulonephritis	0.000522	0.00068	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000512	0.000666	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQA1—membranous glomerulonephritis	0.000495	0.000645	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.000485	0.000631	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000472	0.000614	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000467	0.000608	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—TBXAS1—membranous glomerulonephritis	0.000465	0.000605	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—membranous glomerulonephritis	0.000461	0.0006	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TBXAS1—membranous glomerulonephritis	0.000461	0.0006	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—membranous glomerulonephritis	0.000443	0.000577	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—membranous glomerulonephritis	0.000437	0.00057	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—RHOA—membranous glomerulonephritis	0.000425	0.000554	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000419	0.000545	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LRP2—membranous glomerulonephritis	0.000414	0.000539	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LRP2—membranous glomerulonephritis	0.000411	0.000535	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C3—membranous glomerulonephritis	0.000407	0.000531	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G1B—membranous glomerulonephritis	0.000399	0.000519	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000395	0.000515	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.000391	0.000509	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LRP2—membranous glomerulonephritis	0.000389	0.000507	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C3—membranous glomerulonephritis	0.000387	0.000503	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000386	0.000503	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—membranous glomerulonephritis	0.000371	0.000483	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TBXAS1—membranous glomerulonephritis	0.000366	0.000476	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—membranous glomerulonephritis	0.000352	0.000459	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PLG—membranous glomerulonephritis	0.000347	0.000451	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TBXAS1—membranous glomerulonephritis	0.000344	0.000448	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TBXAS1—membranous glomerulonephritis	0.000344	0.000447	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000343	0.000446	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—membranous glomerulonephritis	0.000338	0.00044	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—membranous glomerulonephritis	0.000332	0.000433	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PLG—membranous glomerulonephritis	0.000329	0.000428	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOA1—membranous glomerulonephritis	0.000329	0.000428	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LRP2—membranous glomerulonephritis	0.000326	0.000425	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TBXAS1—membranous glomerulonephritis	0.000325	0.000423	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000314	0.000409	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000312	0.000407	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.00031	0.000404	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LRP2—membranous glomerulonephritis	0.000307	0.0004	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000307	0.000399	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LRP2—membranous glomerulonephritis	0.000306	0.000399	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000306	0.000399	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000295	0.000385	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000295	0.000384	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LRP2—membranous glomerulonephritis	0.000289	0.000377	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000279	0.000363	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.000275	0.000359	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000272	0.000354	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—membranous glomerulonephritis	0.000267	0.000348	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TBXAS1—membranous glomerulonephritis	0.000266	0.000346	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCA1—membranous glomerulonephritis	0.000265	0.000345	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C3—membranous glomerulonephritis	0.000263	0.000343	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RHOA—membranous glomerulonephritis	0.000252	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C3—membranous glomerulonephritis	0.00025	0.000325	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—membranous glomerulonephritis	0.000245	0.000319	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000243	0.000316	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOA1—membranous glomerulonephritis	0.000242	0.000316	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TBXAS1—membranous glomerulonephritis	0.000242	0.000315	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—membranous glomerulonephritis	0.000242	0.000315	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LRP2—membranous glomerulonephritis	0.000237	0.000308	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—membranous glomerulonephritis	0.000233	0.000303	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOA1—membranous glomerulonephritis	0.00023	0.0003	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—membranous glomerulonephritis	0.000229	0.000299	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000228	0.000297	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.000225	0.000293	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000223	0.00029	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LRP2—membranous glomerulonephritis	0.000216	0.000281	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000216	0.000281	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCA1—membranous glomerulonephritis	0.00021	0.000274	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000208	0.000271	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TBXAS1—membranous glomerulonephritis	0.000207	0.00027	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.000206	0.000268	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000203	0.000265	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCA1—membranous glomerulonephritis	0.000198	0.000258	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCA1—membranous glomerulonephritis	0.000197	0.000257	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCA1—membranous glomerulonephritis	0.000186	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RHOA—membranous glomerulonephritis	0.000186	0.000242	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LRP2—membranous glomerulonephritis	0.000185	0.00024	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G1B—membranous glomerulonephritis	0.000178	0.000231	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000177	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RHOA—membranous glomerulonephritis	0.000176	0.000229	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—membranous glomerulonephritis	0.000176	0.000229	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—membranous glomerulonephritis	0.000174	0.000227	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—membranous glomerulonephritis	0.000174	0.000226	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—membranous glomerulonephritis	0.000172	0.000224	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—membranous glomerulonephritis	0.000165	0.000215	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—membranous glomerulonephritis	0.000163	0.000212	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000161	0.00021	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—membranous glomerulonephritis	0.000153	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—membranous glomerulonephritis	0.000147	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—membranous glomerulonephritis	0.00014	0.000182	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—membranous glomerulonephritis	0.000139	0.000181	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—membranous glomerulonephritis	0.000138	0.00018	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—membranous glomerulonephritis	0.000138	0.000179	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—membranous glomerulonephritis	0.000137	0.000178	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—membranous glomerulonephritis	0.000136	0.000178	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—membranous glomerulonephritis	0.00013	0.000169	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—membranous glomerulonephritis	0.00013	0.000169	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—membranous glomerulonephritis	0.000129	0.000167	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—membranous glomerulonephritis	0.000128	0.000167	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RHOA—membranous glomerulonephritis	0.000125	0.000163	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—membranous glomerulonephritis	0.000123	0.00016	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—membranous glomerulonephritis	0.000121	0.000158	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—membranous glomerulonephritis	0.000119	0.000155	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—membranous glomerulonephritis	0.000108	0.000141	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—membranous glomerulonephritis	0.000102	0.000133	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—membranous glomerulonephritis	0.000102	0.000132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—membranous glomerulonephritis	0.0001	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—membranous glomerulonephritis	9.92e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—membranous glomerulonephritis	9.61e-05	0.000125	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—membranous glomerulonephritis	9.15e-05	0.000119	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—membranous glomerulonephritis	9.05e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—membranous glomerulonephritis	7.86e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—membranous glomerulonephritis	7.82e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—membranous glomerulonephritis	7.73e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—membranous glomerulonephritis	7.17e-05	9.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—membranous glomerulonephritis	6.13e-05	7.98e-05	CbGpPWpGaD
